MEREO BIOPHARMA GROUP PLC Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two
MEREO BIOPHARMA GROUP PLC (MREO) had Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two of $301.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases › Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two $301.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two $205.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two $205.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two $209.00K.
| Period end | Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two |
|---|---|
| 2026-06-30 | $301.00K 10-Q · filed 2026-08-11 |
| 2025-12-31 | $205.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $205.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $209.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $197.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $192.00K 10-K · filed 2025-03-26 |
| 2024-09-30 | $818.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $771.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $771.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $778.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |